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It is thought that insulin resistance syndrome leads to impaired glucose tolerance,
dyslipidemia, hypertension, and impaired fibrinolytic activity.
1 Insulin sensitivity is lower in
patients with essential hypertension when compared with normotensive patients.
2 The
insulinemic response to a glucose load is greater among patients with essential hypertension.
An impaired glucose uptake in cells accompanies this situation.
3 Also, according to the 2002
reports of the American Diabetes Association (ADA), essential hypertension is accepted as
the major risk factor for the development of type 2 diabetes mellitus.
4
We aimed to determine the impaired glucose tolerance and diabetes prevalence in patients
with essential hypertension and to compare the developed microvascular complications of
these groups.
We enrolled 338 subjets in this study from 1998-2002. Blood pressure (BP) was measured
two times in the seated position after about 10 minutes of rest with a standard manual
mercury sphygmomanometer (for nonobese subjects) and an 18 × 42 cm extra large cuff
(for obese subjects). The recorded pressure of the two measurements was averaged.
Subjects with a systolic and diastolic BP equal to or exceeding 140/90 mmHg, and those
who had used BP lowering medications were considered to have hypertension (Table 1).
Secondary causes of hypertension in all patients were excluded, as far as possible, bythe
findings of the following clinical examinations: serum urea, creatinine, electrolytes, thyroid-
stimulating hormone (TSH) and free T4 concentrations, urinary metanephrine, and an over-
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The oral glucose tolerance test (OGTT) was performed on
338 essential hypertensive cases. The results were classified
according to ADA 2002 criteria.
4
We measured the values 2 hours after we had given 75 gr of
glucose to each patient. Those patients whose 2 hour plasma
glucose (2h PG) level was 140-200 mg/dL were evaluated as
having impaired glucose tolerance (IGT), those whose fasting
plasma glucose (FPG) level was ≥ 126 mg/dL or 2h PG was ≥
200 mg/dL were evaluated as having type 2 diabetes mellitus
(DM), and finially those whose FPG was < 126 mg/dL and 2h
PG was < 140 mg/dL were evaluated as having normal glucose
tolerance. None of the cases had the typical clinical character-
istics of DM as their fasting glucose levels were in the normal
range (80-125 mg/dL). None of the patients had been taking any
oral antidiabetic medications or following a calorie restricted
diet before the laboratory evaluation.
We revealed retinopathies and nephropathies in all patients
by performing ophthalmologic examinations and kidney
function tests (creatinin, creatinin clearance, and microalbumi-
nuria) respectively. 30 cases consisted of the control group.
They were chosen from 228 cases of essential hypertension, but
not impaired glucose tolerance, diabetes, anemia, thyroid
disease, neurologic disorders and malignancies, furthermore,
from those cases that had complete results from all parameter
tests. All data were recorded to SPSS 10.0 and evaluated by a
Chi-square test, one way variance analysis, a correlation test,
and logistic regression analysis. 
Out of all the enrolled patients, 32 people had diabetes (DM,
9.46%), 78 people had glucose intolerance (IGT, 23.1%), and
228 people had only hypertension without impaired glucose
tolerance or diabetes (control, 67.4%). The features of these
groups (the control group being 30 cases chosen from the 228
cases) are shown on Table 2.
When compared with the mean age of the control group
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RESULTS
Table 1. Distribution of Antihypertensive Medications According 
to Groups
Antyhypertensive Control IGT DM   
medication group (%) group (%) group (%)
Diuretics 36 32 20
α-blockers 16 30 31
β-blockers 20 9 9.3
Calcium channel 
36 40 34
blockers
ACEI’s 60 40 60
AT II blockers 10 28 22
IGT, impaired glucose tolerance; ACEI, angiotensin-converting enzyme inhibitor.
Table 2.Features and Comparison of the Mean Values of the Control, IGT and DM Groups
Control group IGT group DM group Significant
Cases (n) 30 78 32
Age (yr) 51.1 ± 6.4 56.3 ± 8.4 56.9 ± 6.7 p = 0.003
Sex (M / F) 14 E, 16 K 17 E, 61 K 12 E, 20 K p = 0.004
HT duration (yr) 7.6 ± 5.3 8.9 ± 6 10.8 ± 7.3 NS
Diabetes history in family (yes / no) 5 / 25 19 / 59 3 / 29 NS
BMI (kg / m
2 ) 30.4 ± 4.8 31.1 ± 4.7 30.17 ± 4.1 NS
Fasting plasma glucose (mg / dL) 99.1 ± 14 100.9 ± 13 115.5 ± 13 NS
HbA1c (%) - 5.4 ± 0.9 5.8 ± 0.9 NS
Insülin (IU) 12.9 ± 2.9 11.4 ± 1.2 9.8 ± 1.2 NS
HOMA-R 3.1  ± 0.8 2.2 ± 0.6 2.7 ± 0.4 NS
Systolic blood pressure (mmHg) 158.5 ± 22 168.9 ± 22 161.4 ± 23 NS
Diastolic blood pressure (mmHg) 103.1 ± 10 101.7 ± 12.5 98.5 ± 11 NS
Tryglycerid (mg / dL) 171.7 ± 74 188.7 ± 100 182.1 ± 84 NS
Cholesterol (mg / dL) 219.1 ± 40 227.6 ± 50 223.1 ± 36 NS
LDL-cholesterol (mg / dL) 138.8 ± 31 141.9 ± 45 136.7 ± 32.6 NS
HDL-cholesterol (mg / dL) 45.1 ± 8.5 48.3 ± 11.4 47.9 ± 10.1 NS
Uric acid (mg / dL) 6.1 ± 5.1 4.8 ± 1.5 5.1 ± 2.2 NS
Creatinin (mg / dL) 0.97 ± 0.2 0.89 ± 1 0.93 ± 0.2 NS
Creatinin clearance (mL / dk) 95.3 ± 29 91.8 ± 29 86 ± 23 NS
Microalbuminuria (mg / day) 29.8 ± 33 29.2 ± 23 30.5 ± 10.4 NS
IGT, impaired glucose tolerance; DM, diabetes mellitus; HT, hypertension; BMI, body mass index; AbAlc, hemoglobin A1c; HOMA-R, 
homeostasis model assessment index ratio; LDL, low density lipoprotein; HDL, high density lipoprotein.(51.1  ± 6.4 years), both the mean ages of the DM group (56.9
± 6.7 years; p = 0.002) and IGT group (56.3±8.4 years; p =
0.003) were older. The age variance among these three groups
(p = 0.003) was highly significant according to the one way
variance analysis (Fig. 1). 
In the DM group there were 12 men and 20 women, in the
IGT group there were 17 men and 61 women, and in the
control group there were 14 men and 16 women (Fig. 2).
According to the logistic regression analysis, the risk of IGT
development was found to be four times greater in male cases
than in female cases when compared to the control group (p =
0.004, odd ratio = 4.194).
The body mass indexes (BMIs) of the groups were as follows:
30.17 ± 4.1 kg/m
2 in the DM group, 31.1 ± 4.7 kg/m
2 in the IGT
group, and 30.42 ± 4.8 kg/m
2 in the control group. There was no
significant difference in the BMIs among these groups (Fig. 3).
Patients had hypertension for 10.8 ± 7.3 years in the DM
group, 8.9 ± 6 years in the IGT group, and 7.6 ± 5.3 years in the
control group (Fig. 4). There was no statistically significant
difference among these durations.
5 patients in the DM group, 19 patients in the IGT group, and
3 patients in the control group had a history of diabetes in their
families; these values were not statistically different. These
results are given in Fig. 5.
Among these groups, a significant difference could not be
evaluated from the values of FPG, total cholesterol, low density
lipoprotein (LDL) cholesterol, high density lipoprotein (HDL)
cholesterol, triglyceride, uric acid, hemoglobin Alc (HbA1c),
homeostasis model assessment index ratio (HOMA-R), mean
systolic and diastolic blood pressures (Table 2). 
The ophthalmologic examinations of all patients were
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Fig. 1. Mean ages of three groups. IGT, impaired glucose tolerance; DM, diabetes
mellitus.
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Fig. 2. Number of male and female subjects in three groups. IGT, impaired glucose
tolerance; DM, diabetes mellitus.
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Fig. 3.Means of BMI of three groups. IGT, impaired glucose tolerance; DM, diabetes
mellitus; BMI, body mass index; NS, statistically non-significant.
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Fig. 5. Number of patients having a familial hypertension history in three groups. IGT,
impaired glucose tolerance; DM, diabetes mellitus; NS, statistically non-significant.
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Fig. 4. Duration of hypertension in three groups. IGT, impaired glucose tolerance;
DM, diabetes mellitus; NS, statistically non-significant.evaluated regarding hypertensive retinopathy and diabetic
retinopathy. Diabetic retinopathy was not found in both the DM
and IGT groups. Hypertensive retinopathy, which had been
detected in all patients, was at greater levels in both the DM and
IGT groups (p = 0.039).
The microalbuminuria (MA) level (30-300 mg/day), which
had been used as the nephropathy parameter, was 30.5 ± 10.4
mg/day in the DM group, 29.2 ± 23 mg/day in the IGT group,
and 29.8 ± 33 mg/day in the control group. There were no
significant differences among these results. For all three groups,
there was no significant relationship between the presence of
MA and hypertensive retinopathy or BMI.
In the series of studies, the presence of a family history of
diabetes, impaired glucose tolerance, hypertension (HT), and an
increase in BMI were found to be independent risk factors for
the development of diabetes.
4-6 It has been reported that
changing ones life style (to lessen obesity, increasing physical
activities, chaging nutritional habits) causes a serious decrease,
or at least a delay, in the development of diabetes.
7,8
The morbidity and mortality of cardiovascular system (CVS)
disorders are increased in the DM group. They are also
increased in the impaired fasting glucose (IFG) and IGT
groups. Thus, the detection of IFG and IGT in patients has
more diagnostic value.
9-11 As a result of these studies, investi-
gations have been held in recent years to find a better glucose
cut off value to determine the risk of diabetes.
5,10-12
Obesity, smoking, IGT, hyperlipidemia, and HT are the risk
factors for cardiovascular disease.
13,14 It has been determined
that hyperinsulinemia and an impaired glucose uptake in
muscle cells are seen in essential HT.
3
We aimed to investigate IGT and DM in patients with
essential hypertension. When we evaluated the OGTT results of
338 cases by ADA 2002 criteria, we found that 23.1% had IGT
and 9.46% had DM (not known before).
From epidemiological studies DM and IGT prevalences have
been found to be 6-15% and 15-24% respectively, both of
which have greatly increased in the last few decades.
6,15-18
According to the Turkish Diabetes Epidemiology Prevalence
Study (TURDEP),
19 DM prevalence is 7.2%, IGT prevalence is
6.7%, and HT prevalence is 29% in the general public. Among
the people who have HT, DM prevalence is 16.1%, and IGT
prevalence is 11.6%. In another investigation from our country,
20
DM prevalence is 10.58% and IGT prevalence is 24.11%
according to ADA criteria. From these results, it is obvious that
the DM and IGT prevalences of hypertensive patients are not
very different from epidemiological prevalences.
The increase in DM prevalence as a result of modernization
and longer life spans is important.
6,16 Similar to these studies, in
our study the mean ages of the IGT and DM groups were
significantly higher than that of the control group (p = 0.003).
This supports the findings that a decrease in insulin sensitivity
in a middle aged person will lead to obvious impaired glucose
tolerance in older ages.
21 Age and glucose levels are the
independent risk factors that decrease the glomerular filtration
rate. Thus, investigating IGT, especially in patients who have
HT, is a possible determinant of renal failure due to aging.
22
In previous studies it has been reported that DM, IGT, and
IFG prevalences are found to be higher in males.
5,6,12,15 Macro-
vascular diseases are more frequent in female diabetics.
17 Also,
in women who have HT, an important relationship between
IGT and obesity (which are cardiovascular risk factors) exists.
13
In our study, the risk of IGT development was four times
higher in male patients than in female patients when compared
with the control group.
An increase in obesity in developed countries in the last 3
decades and the risk of DM development due to obesity and its
duration has led to the suggestion of forming the term diabesity.
6
IGT prevalence is also high in seriously obese children and
adolescents, and in these groups, serious obesity plays a role in
type 2 DM pathogenesis.
23 Obesity is also a serious risk factor
for cardiovascular diseases.
11
In our study, there was no significant difference between the
BMIs of the groups, but all BMIs were above the cut off value
for obesity, which causes a risk for IGT, DM, cardiovascular
diseases and HT. Although a significant difference in the levels
of lipids, FPG, HOMA-R, and BMI could not be evaluated
amomg the groups, we think that BMI values, when above the
cut off values, are important for glucose metabolism distur-
bance which develops in HT cases. HT prevalence is high in
DM and IGT groups.
5,11,13,15 It has been determined that 2h PG
levels have damaging effects on the endothelial functions in
patients who have HT.
24
In the current study, although the result was not significant in
both the DM group and IGT group, the hypertension durations
were longer than that of the control group. It seems that age and
the length of HT duration increase the probability of having
IGT.
The frequencies of retinopathy and nephropathy have been
shown to have a direct relationship with fasting glucose and 2h
postprandial plasma glucose.
25 We didn’t determine diabetic
retinopathy in either the DM or IGT group. 
The hypertensive retinopathy level was in a higher state in
both groups (p = 0.039, Grade II or III). This incidence may be
explained by longer hypertensive durations.
The development of MA, which is important for the
diagnosis and classification of nephropathy, increases with long
term hyperglicemia and subdiabetic glycemia.
26,27 The MA level
was not significantly different among the groups, but the mean
values of all three groups were at the minimal cut off value of
MA. This can be explained by hypertension which causes
endothelial damage. MA is reported as the strongest determi-
nant of cardiovascular mortality in patients having type 2 DM,
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IFG/IGT, and insulin resistance.
28
In conclusion, we think that the risk of IGT and DM develop-
ment in HT cases increases with aging and longer HT duration.
The risk of IGT development in hypertensive cases is four
times higher in males.
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